NCT06083883View on ClinicalTrials.gov

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2028

Conditions
Synovial SarcomaMyxoid/Round Cell Liposarcoma
Interventions
DRUG

Fludarabine phosphate

Given by IV (vein)

DRUG

NY-ESO-1 TCR/IL-15 NK

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER